Vaxcyte Inc (PCVX)
Vaxcyte, Inc. is a clinical-stage biotechnology company focused on developing conjugate and novel protein vaccines aimed at preventing or treating bacterial infectious diseases. Its pipeline includes VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for invasive pneumococcal disease in infants, and VAX-31, a 31-valent carrier-sparing candidate being studied for adults and children. The company is also advancing VAX-A1 for Group A Streptococcus, VAX-PG for periodontitis, VAX-GI for dysentery and shigellosis caused by Shigella bacteria, and VAX-XL, a third-generation pneumococcal conjugate vaccine. Founded in 2013 and headquartered in San Carlos, California, the company was previously known as SutroVax, Inc. before changing its name in May 2020. Vaxcyte’s common stock is listed on NASDAQ under the ticker PCVX.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-PCVX
|
$51.69
|
-11.1% Downside
|
Fair
|
$109
|
87.5% Upside
|
Bargain
|
Fair
|
0.0%
|
November 9, 2026
|
3.1x
|
8.652 B
|
6.258 B
|
1.3%
|
91.7%
|
12.2
|
86.5%
|
